We conducted an international, randomized, phase 3 trial comparing second-line trastuzumab deruxtecan at a dose of 6.4 mg per kilogram of body weight with ramucirumab plus paclitaxel in patients ...

CHICAGO — Trastuzumab deruxtecan extended PFS compared with standard chemotherapy for certain patients with pretreated breast cancer, according to findings presented at ASCO Annual Meeting.

Topline data were announced from a phase 3 trial evaluating fam-trastuzumab deruxtecan-nxki followed by THP in patients with high-risk, locally advanced HER2-positive early stage breast cancer.

Patients with early breast cancer when trastuzumab was given as neoadjuvant therapy (RR, 1.30; 95% CI, 0.47-3.59; with consistency across studies, I 2 = 0%; P =.57).

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

Trastuzumab deruxtecan (6.4 mg/kg) is approved in several countries for the treatment of adult patients with locally advanced or metastatic HER2 positive gastric or gastroesophageal junction (GEJ ...

Chen AJ, Kaiser KM, Gascue L, Manetas M-A, Van Nuys K. Cancer drug trastuzumab and its biosimilars compete on price for market share. Health Affairs (Millwood) . 2023;42(6):779-784. doi:10.1377 ...

In patients with metastatic HER2 (ERBB2)-mutant (HER2m) non­–small cell lung cancer (NSCLC), the presence of brain metastases (BM) did not affect response to treatment with trastuzumab ...

Breast Cancer Now said the approval of cancer treatment Trastuzumab deruxtecan ushered an “exciting new era” of treatment. It is among four different cancer treatments approved for use by NHS ...